E-Mail
New York, NY (April 10, 2021) - A personalized cancer vaccine developed with the help of a Mount Sinai computational platform raised no safety concerns and showed potential benefit in patients with different cancers, including lung and bladder, that have a high risk of recurrence, according to results from an investigator-initiated phase I clinical trial presented during the virtual American Association for Cancer Research (AACR) Annual Meeting 2021, held April 10-15. While immunotherapy has revolutionized the treatment of cancer, the vast majority of patients do not experience a significant clinical response with such treatments, said study author Thomas Marron, MD, PhD, Assistant Director for Early Phase and Immunotherapy Trials at The Tisch Cancer Institute and Assistant Professor of Medicine (Hematology and Medical Oncology) at the Icahn School of Medicine at Mount Sinai. Cancer vaccines, which typically combine tumor-specific targets that the immune system can lear
Cancer Patients May Benefit From Fecal Transplant - Guardian Liberty Voice guardianlv.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from guardianlv.com Daily Mail and Mail on Sunday newspapers.
Fecal transplant overcomes resistance to immunotherapy in melanoma patients
Researchers at UPMC Hillman Cancer Center and the National Cancer Institute (NCI) demonstrate that changing the gut microbiome can transform patients with advanced melanoma who never responded to immunotherapy-;which has a failure rate of 40% for this type of cancer-;into patients who do.
The results of this proof-of-principle phase II clinical trial were published online today in
Science. In this study, a team of researchers from UPMC Hillman administered fecal microbiota transplants (FMT) and anti-PD-1 immunotherapy to melanoma patients who had failed all available therapies, including anti-PD-1, and then tracked clinical and immunological outcomes. Collaborators at NCI analyzed microbiome samples from these patients to understand why FMT seems to boost their response to immunotherapy.
Fecal Microbiome Transplant Converts Melanoma Immunotherapy Non-Responders into Responders
February 5, 2021
Scientists at the NIH in collaboration with UPMC Hillman Cancer Center have shown how some patients with advanced melanoma that hasn’t responded to immune checkpoint inhibitor therapy, can be converted to immunotherapy responders by giving them a fecal microbiota transplant (FMT), taken from patients who had responded very well to immunotherapy. Results from the proof-of-principle Phase II study, reported in
Science, suggest that introducing certain fecal microorganisms into a patient’s colon may help individuals respond to drugs that enhance the immune system’s ability to recognize and kill tumor cells.
Credit: UPMC
PITTSBURGH, Feb. 4, 2021 - Researchers at UPMC Hillman Cancer Center and the National Cancer Institute (NCI) demonstrate that changing the gut microbiome can transform patients with advanced melanoma who never responded to immunotherapy which has a failure rate of 40% for this type of cancer into patients who do.
The results of this proof-of-principle phase II clinical trial were published online today in Science. In this study, a team of researchers from UPMC Hillman administered fecal microbiota transplants (FMT) and anti-PD-1 immunotherapy to melanoma patients who had failed all available therapies, including anti-PD-1, and then tracked clinical and immunological outcomes. Collaborators at NCI analyzed microbiome samples from these patients to understand why FMT seems to boost their response to immunotherapy.